Abby... There are several indications for which Iplex™ is being considered. And to get the drug through phase III trials, and approval will take a lot of money. That is where a BIG partner would make a huge difference for this small company, and would pave the way for a much faster approval, and development. Either way, Insmed looks to me to be a great bargain at these prices, especially when compared to other biotechs.. some of which do not even have an approved drug yet. GLTY
Market Data 
Markets 
AI
